Literature DB >> 7519877

A 3-Mb physical map of the chromosome region 8p21.3-p22, including a 600-kb region commonly deleted in human hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer.

Y Fujiwara1, H Ohata, M Emi, K Okui, K Koyama, E Tsuchiya, T Nakajima, M Monden, T Mori, A Kurimasa.   

Abstract

To isolate a putative tumor suppressor gene(s), we have constructed a physical map and a detailed deletion map of chromosome region 8p21.3-p22, where loss of heterozygosity (LOH) has been frequently seen in human hepatocellular carcinomas (HCC), colorectal cancers (CRC), and non-small cell lung cancers (NSCLC). The smallest commonly deleted region at 8p21.3-p22 in HCC and CRC was between the loci defined by C18-245 and C18-2644; in NSCLC, a region between C18-1051 and C18-2644 was commonly deleted. A contiguous physical map of 12 cosmid markers in the 8p21.3-p22 region was constructed by means of multi-color fluorescence in situ hybridization (FISH) and pulsed-field gel electrophoresis (PFGE). On the basis of this physical map, which spans roughly 3.1 Mb, the estimated sizes of the commonly deleted regions were at most 1.2 Mb in HCC and CRC and 0.6 Mb in NSCLC. As four of the 12 physically ordered markers are located within the 0.6 Mb region commonly deleted in all three tumor types, nearly one fourth to one fifth of the target region has already been covered with cosmid inserts.

Entities:  

Mesh:

Year:  1994        PMID: 7519877     DOI: 10.1002/gcc.2870100103

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  18 in total

1.  High-resolution physical map and transcript identification of a prostate cancer deletion interval on 8p22.

Authors:  Z H Arbieva; K Banerjee; S Y Kim; S L Edassery; V S Maniatis; S K Horrigan; C A Westbrook
Journal:  Genome Res       Date:  2000-02       Impact factor: 9.043

2.  Genetic mapping of farnesyltransferase alpha(Fnta) to mouse chromosome 8.

Authors:  J C Porter; A Messer
Journal:  Mamm Genome       Date:  1996-08       Impact factor: 2.957

3.  Loss of heterozygosity: an independent prognostic factor of colorectal cancer.

Authors:  Shih-Ching Chang; Jen-Kou Lin; Tzu-Chen Lin; Wen-Yih Liang
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

4.  Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer.

Authors:  U Wagner; L Bubendorf; T C Gasser; H Moch; J P Görög; J Richter; M J Mihatsch; F M Waldman; G Sauter
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

5.  Gain of chromosome 20 is a frequent aberration in liver metastasis of colorectal cancers.

Authors:  A Nanashima; H Yamaguchi; T Yasutake; T Sawai; H Kusano; Y Tagawa; T Nakagoe; H Ayabe
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

Review 6.  Review of allelic loss and gain in prostate cancer.

Authors:  G S Bova; W B Isaacs
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

7.  Palmitoylation of cytoskeleton associated protein 4 by DHHC2 regulates antiproliferative factor-mediated signaling.

Authors:  Sonia L Planey; Susan K Keay; Chen-Ou Zhang; David A Zacharias
Journal:  Mol Biol Cell       Date:  2009-01-14       Impact factor: 4.138

8.  Identification of CKAP4/p63 as a major substrate of the palmitoyl acyltransferase DHHC2, a putative tumor suppressor, using a novel proteomics method.

Authors:  Jun Zhang; Sonia L Planey; Carolina Ceballos; Stanley M Stevens; Susan K Keay; David A Zacharias
Journal:  Mol Cell Proteomics       Date:  2008-02-22       Impact factor: 5.911

9.  Allelic imbalance of 8p indicates poor survival in gastric cancer.

Authors:  Amy J French; Gina Petroni; Stephen N Thibideau; Mark Smolkin; Eric Bissonette; Franco Roviello; Jeffrey C Harper; Benjamin R Koch; Sarah A Anderson; Scott J Hebbring; Steven M Powell
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

10.  Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2.

Authors:  Yuan-Xue Jiang; Zi-Ming Du; Lin Jiao; Qiong Shao; Sha Fu; Jian-Yong Shao; Xiao-Feng Zhu; Ingemar Ernberg; Yu-Hong Li
Journal:  Int J Clin Exp Med       Date:  2015-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.